Additional Prognostic Value of Tumor Grade Beyond the 21-gene Recurrence Score
NCT ID: NCT07093775
Last Updated: 2025-07-30
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
NOT_YET_RECRUITING
4000 participants
OBSERVATIONAL
2025-07-31
2026-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Recurrence Risk Evaluation by 21-gene Detection
NCT03841266
Parallel Comparison of 18 Gene Classifiers and Oncotype DX (Nanostring)
NCT03772197
Distribution of the Homologous Recombination-related (HRR) Genesmutationsand HRD in Breast Cancer
NCT05466786
Miti-gene Recurrence Score in HR+/HER2- Chinese Breast Cancer Patients
NCT07052734
A Composite Assay for HER2-positive Early-stage Breast Cancer Management
NCT06762977
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Tumor grade (I or II vs. III)
We compared the prognosis according to the tumor grade stratified by 21-gene recurrence score
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Patients treated between January 2011 and December 2023
* Patients with available clinicopathologic data and 21-gene Oncotype DX assay results confirmed through electronic medical records
Exclusion Criteria
* Patients diagnosed with stage IV breast cancer
* Patients for whom clinicopathologic data cannot be retrieved from electronic medical records
20 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Gangnam Severance Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sung Gwe Ahn
Professor
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3-2025-0107
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.